Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 2Phase 1 2Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myeloproliferative Syndrome, Transient 1Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1Congenital Abnormalities 1Chromosome 5q Deletion Syndrome 1

Interventions

ruxolitinib 6Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5Cytarabine 5fludarabine phosphate 4Whole-Body Irradiation 4Methotrexate 4Daunorubicin 4Thioguanine 3Tacrolimus 3Etoposide 3Early Intervention, Educational 3Cyclophosphamide 3ponatinib 2parsaclisib 2nilotinib 2merphos 2luspatercept 2fludarabine 2fedratinib 2anagrelide 2Tretinoin 2Therapeutics 2Psychiatric Rehabilitation 2Mitoxantrone 2Filgrastim 2Cyclosporins 2Cyclosporine 2Busulfan 2Asparaginase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Myeloproliferative Disorders × Flow Cytometry × Clear all
NCT00322101 2014-10-31

Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Fred Hutchinson Cancer Center

Phase 3 Completed
25 enrolled 13 charts
MyeloidOther hematologic neoplasm

Chromosome 5q Deletion Syndrome, Myeloproliferative Syndrome, Transient, Congenital Abnormalities, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡